Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.
2.

SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.

Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K.

Cancer Immunol Res. 2019 Mar;7(3):414-427. doi: 10.1158/2326-6066.CIR-18-0126. Epub 2019 Jan 4.

PMID:
30610059
3.

Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?

Coss CC, Clinton SK, Phelps MA.

Clin Cancer Res. 2018 Dec 1;24(23):5787-5789. doi: 10.1158/1078-0432.CCR-18-1847. Epub 2018 Jul 17.

PMID:
30018117
4.

Phyllanthusmin Derivatives Induce Apoptosis and Reduce Tumor Burden in High-Grade Serous Ovarian Cancer by Late-Stage Autophagy Inhibition.

Young AN, Herrera D, Huntsman AC, Korkmaz MA, Lantvit DD, Mazumder S, Kolli S, Coss CC, King S, Wang H, Swanson SM, Kinghorn AD, Zhang X, Phelps MA, Aldrich LN, Fuchs JR, Burdette JE.

Mol Cancer Ther. 2018 Oct;17(10):2123-2135. doi: 10.1158/1535-7163.MCT-17-1195. Epub 2018 Jul 17.

5.

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.

Badawi M, Kim J, Dauki A, Sutaria D, Motiwala T, Reyes R, Wani N, Kolli S, Jiang J, Coss CC, Jacob ST, Phelps MA, Schmittgen TD.

Oncotarget. 2018 May 25;9(40):26032-26045. doi: 10.18632/oncotarget.25430. eCollection 2018 May 25.

6.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R.

Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.

7.

Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA.

PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017.

8.

Development of selective androgen receptor modulators (SARMs).

Narayanan R, Coss CC, Dalton JT.

Mol Cell Endocrinol. 2018 Apr 15;465:134-142. doi: 10.1016/j.mce.2017.06.013. Epub 2017 Jun 15. Review.

9.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC.

PLoS One. 2016 Jul 19;11(7):e0159607. doi: 10.1371/journal.pone.0159607. eCollection 2016.

10.

Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Coss CC, Jones A, Dalton JT.

Invest New Drugs. 2016 Aug;34(4):458-67. doi: 10.1007/s10637-016-0353-8. Epub 2016 Apr 22.

PMID:
27105861
11.

Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.

Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan KK.

AAPS J. 2016 May;18(3):737-45. doi: 10.1208/s12248-016-9876-3. Epub 2016 Mar 4.

12.

Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.

Yu EY, Getzenberg RH, Coss CC, Gittelman MM, Keane T, Tutrone R, Belkoff L, Given R, Bass J, Chu F, Gambla M, Gaylis F, Bailen J, Hancock ML, Smith J, Dalton JT, Steiner MS.

Eur Urol. 2015 Feb;67(2):334-41. doi: 10.1016/j.eururo.2014.06.011. Epub 2014 Jun 24.

PMID:
24968970
13.

Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer.

Coss CC, Jones A, Dalton JT.

Steroids. 2014 Nov;90:94-100. doi: 10.1016/j.steroids.2014.06.010. Epub 2014 Jun 16. Review.

PMID:
24945109
14.

Selective androgen receptor modulators for the treatment of late onset male hypogonadism.

Coss CC, Jones A, Hancock ML, Steiner MS, Dalton JT.

Asian J Androl. 2014 Mar-Apr;16(2):256-61. doi: 10.4103/1008-682X.122339. Review.

15.

Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.

Narayanan R, Yepuru M, Coss CC, Wu Z, Bauler MN, Barrett CM, Mohler ML, Wang Y, Kim J, Snyder LM, He Y, Levy N, Miller DD, Dalton JT.

PLoS One. 2013 Dec 26;8(12):e83380. doi: 10.1371/journal.pone.0083380. eCollection 2013.

16.

Effect of para halogen modification of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides on metabolism and clearance.

Kim J, Coss CC, Dalton JT.

Arch Pharm Res. 2014 Nov;37(11):1464-76. doi: 10.1007/s12272-013-0258-4. Epub 2013 Oct 9.

PMID:
24105418
17.

Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen.

Kim J, Coss CC, Barrett CM, Mohler ML, Bohl CE, Li CM, He Y, Veverka KA, Dalton JT.

Int J Cancer. 2013 Mar 15;132(6):1475-85. doi: 10.1002/ijc.27794. Epub 2012 Sep 14.

18.

Androgen receptor antagonists: a patent review (2008-2011).

Mohler ML, Coss CC, Duke CB 3rd, Patil SA, Miller DD, Dalton JT.

Expert Opin Ther Pat. 2012 May;22(5):541-65. doi: 10.1517/13543776.2012.682571. Review.

PMID:
22583332
19.

Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.

Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, Veverka KA, Miller DD, Morton RA, Steiner MS, Dalton JT.

Endocrinology. 2012 Mar;153(3):1070-81. doi: 10.1210/en.2011-1608. Epub 2012 Jan 31.

PMID:
22294742
20.

Alanine aminotransferase regulation by androgens in non-hepatic tissues.

Coss CC, Bauler M, Narayanan R, Miller DD, Dalton JT.

Pharm Res. 2012 Apr;29(4):1046-56. doi: 10.1007/s11095-011-0649-5. Epub 2011 Dec 14.

PMID:
22167351
21.

Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTx-134.

Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG, Trudel S.

Clin Cancer Res. 2011 Jul 15;17(14):4693-704. doi: 10.1158/1078-0432.CCR-10-3097. Epub 2011 Jun 1.

22.

Cancer cachexia therapy: a key weapon in the fight against cancer.

Coss CC, Bohl CE, Dalton JT.

Curr Opin Clin Nutr Metab Care. 2011 May;14(3):268-73. doi: 10.1097/MCO.0b013e3283455e21. Review.

PMID:
21415732
23.

2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.

Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT.

Int J Oncol. 2010 Oct;37(4):1023-30.

PMID:
20811725
24.

GTx-822, an ER{beta}-selective agonist, protects retinal pigment epithelium (ARPE-19) from oxidative stress by activating MAPK and PI3-K pathways.

Giddabasappa A, Bauler MN, Barrett CM, Coss CC, Wu Z, Miller DD, Dalton JT, Eswaraka JR.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5934-42. doi: 10.1167/iovs.10-5630. Epub 2010 Jun 16.

PMID:
20554624
25.

Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications.

Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD, Dalton JT.

Expert Opin Ther Pat. 2010 Apr;20(4):507-34. doi: 10.1517/13543771003657164. Review.

PMID:
20302450
26.

Mechanism of action of bolandiol (19-nortestosterone-3beta,17beta-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities.

Attardi BJ, Page ST, Hild SA, Coss CC, Matsumoto AM.

J Steroid Biochem Mol Biol. 2010 Feb 15;118(3):151-61. doi: 10.1016/j.jsbmb.2009.11.008. Epub 2009 Nov 24.

27.

Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.

Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD.

J Med Chem. 2009 Jun 25;52(12):3597-617. doi: 10.1021/jm900280m. Review. No abstract available.

PMID:
19432422
28.

Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways.

Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT.

Mol Endocrinol. 2008 Nov;22(11):2448-65. doi: 10.1210/me.2008-0160. Epub 2008 Sep 18.

PMID:
18801930
29.

Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.

Gao W, Reiser PJ, Coss CC, Phelps MA, Kearbey JD, Miller DD, Dalton JT.

Endocrinology. 2005 Nov;146(11):4887-97. Epub 2005 Aug 11.

Supplemental Content

Support Center